Vijay Kodumudi1, Kanishka Rajput2. 1. Yale University School of Medicine, 333 Cedar St, TMP3, CT, 06510, New Haven, USA. 2. Yale University School of Medicine, 333 Cedar St, TMP3, CT, 06510, New Haven, USA. kanishka.rajput@yale.edu.
Abstract
PURPOSE OF REVIEW: Psoriasis and psoriatic arthropathy are inflammatory autoimmune conditions that can lead to profound emotional distress, social stigmatization, isolation, disfigurement, pain, disability, unemployment, and decreased quality of life. Thus, this disease has immense psychological, social, and economic implications as the pain experienced is closely associated with the primary disease burden. This review focuses on discussing the primary disease burden of psoriasis and psoriatic arthropathy, as well as management of different types of pain in these patients. RECENT FINDINGS: Pain affects over 40% of patients with psoriasis, ranging from neuropathic to nociceptive. Treatment of pain largely focuses on treating the underlying disease with mild topical steroids and non-steroidal medications including vitamin D analogs followed by systemic immunomodulatory agents for more severe disease. Interventional options such as corticosteroid injections are available for select cases (conditional recommendation). Psoriasis and psoriatic arthropathy have been associated with underreporting and resultant undertreatment of pain. Pain control in these conditions is complex and requires a multidisciplinary approach. More research and guidelines are needed in the areas of reporting of psoriatic disease, associated pain, psoriatic nociception, and optimal clinical management.
PURPOSE OF REVIEW: Psoriasis and psoriatic arthropathy are inflammatory autoimmune conditions that can lead to profound emotional distress, social stigmatization, isolation, disfigurement, pain, disability, unemployment, and decreased quality of life. Thus, this disease has immense psychological, social, and economic implications as the pain experienced is closely associated with the primary disease burden. This review focuses on discussing the primary disease burden of psoriasis and psoriatic arthropathy, as well as management of different types of pain in these patients. RECENT FINDINGS:Pain affects over 40% of patients with psoriasis, ranging from neuropathic to nociceptive. Treatment of pain largely focuses on treating the underlying disease with mild topical steroids and non-steroidal medications including vitamin D analogs followed by systemic immunomodulatory agents for more severe disease. Interventional options such as corticosteroid injections are available for select cases (conditional recommendation). Psoriasis and psoriatic arthropathy have been associated with underreporting and resultant undertreatment of pain. Pain control in these conditions is complex and requires a multidisciplinary approach. More research and guidelines are needed in the areas of reporting of psoriatic disease, associated pain, psoriatic nociception, and optimal clinical management.
Authors: Steven R Feldman; Bernard Goffe; Gary Rice; Matthew Mitchell; Mandeep Kaur; Debbie Robertson; Debra Sierka; Jeffrey A Bourret; Tamara S Evans; Alice Gottlieb Journal: Am Health Drug Benefits Date: 2016-12
Authors: Stefan C Weiss; Alexa B Kimball; David J Liewehr; Andrew Blauvelt; Maria L Turner; Ezekiel J Emanuel Journal: J Am Acad Dermatol Date: 2002-10 Impact factor: 11.527
Authors: Tone Marte Ljosaa; Tone Rustoen; Cato Mörk; Audun Stubhaug; Christine Miaskowski; Steven M Paul; Astrid K Wahl Journal: Acta Derm Venereol Date: 2010 Impact factor: 4.437